Trial · NCT02477696
Results by group126
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 126
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression-free Survival (PFS) Based on Independent Review Committee (IRC) Assessment | Acalabrutinib | 38.4 | 95% Confidence Interval 33.0 to 38.6 | Months | |
| Progression-free Survival (PFS) Based on Independent Review Committee (IRC) Assessment | Ibrutinib | 38.4 | 95% Confidence Interval 33.0 to 41.6 | Months | |
| Number of Participants With Treatment-emergent Infections Grade >= 3 | Acalabrutinib | 98 | Participants | ||
| Number of Participants With Treatment-emergent Infections Grade >= 3 | Ibrutinib | 101 | Participants | ||
| Number of Participants With Treatment-emergent Richter's Transformation | Acalabrutinib | 13 | Participants | ||
| Number of Participants With Treatment-emergent Richter's Transformation | Ibrutinib | 14 | Participants | ||
| Number of Participants With Treatment-emergent Atrial Fibrillation | Acalabrutinib | 32 | Participants | ||
| Number of Participants With Treatment-emergent Atrial Fibrillation | Ibrutinib | 49 | Participants | ||
| Overall Survival (OS) | Acalabrutinib | NA | 95% Confidence Interval NA to NA | Months | |
| Overall Survival (OS) | Ibrutinib | NA | 95% Confidence Interval 65.0 to NA | Months | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) | Acalabrutinib | Any TEAEs | 262 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) | Ibrutinib | Any TEAEs | 259 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) | Acalabrutinib | Any TESAEs | 161 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) | Ibrutinib | Any TESAEs | 177 | Participants | |
| Number of Participants With Treatment-emergent Laboratory Abnormalities | Acalabrutinib | Absolute neutrophil count (decreased) | 124 | Participants | |
| Number of Participants With Treatment-emergent Laboratory Abnormalities | Ibrutinib | Absolute neutrophil count (decreased) | 135 | Participants | |
| Number of Participants With Treatment-emergent Laboratory Abnormalities | Acalabrutinib | Haemoglobin (decreased) | 139 | Participants | |
| Number of Participants With Treatment-emergent Laboratory Abnormalities | Ibrutinib | Haemoglobin (decreased) | 131 | Participants | |
| Number of Participants With Treatment-emergent Laboratory Abnormalities | Acalabrutinib | Platelets (decreased) | 119 | Participants | |
| Number of Participants With Treatment-emergent Laboratory Abnormalities | Ibrutinib | Platelets (decreased) | 116 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02477696/results